Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Operating Expenses (2020 - 2025)

Oncology Institute (TOI) has disclosed Operating Expenses for 6 consecutive years, with $144.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 27.13% year-over-year to $144.6 million, compared with a TTM value of $502.1 million through Sep 2025, up 13.5%, and an annual FY2024 reading of $453.5 million, up 13.03% over the prior year.
  • Operating Expenses was $144.6 million for Q3 2025 at Oncology Institute, up from $131.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $144.6 million in Q3 2025 and bottomed at $50.3 million in Q1 2021.
  • Average Operating Expenses over 5 years is $96.2 million, with a median of $96.5 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 132097.83% in 2021, then grew 1.49% in 2025.
  • Year by year, Operating Expenses stood at $93.1 million in 2021, then grew by 3.62% to $96.5 million in 2022, then increased by 4.74% to $101.1 million in 2023, then rose by 11.0% to $112.2 million in 2024, then rose by 28.9% to $144.6 million in 2025.
  • Business Quant data shows Operating Expenses for TOI at $144.6 million in Q3 2025, $131.0 million in Q2 2025, and $114.3 million in Q1 2025.